loading page

Subcutaneous Administration of Cytarabine for Pediatric Patients with Langerhans Cell Histiocytosis Decreases Burden of Patient Travel and Infusion Center Utilization
  • +2
  • Jennifer R. Blase,
  • Aarti Kamat,
  • David Frame,
  • Rama Jasty,
  • Kelly Walkovich
Jennifer R. Blase
University of Michigan

Corresponding Author:[email protected]

Author Profile
Aarti Kamat
University of Michigan
Author Profile
David Frame
University of Michigan College of Pharmacy
Author Profile
Rama Jasty
University of Michigan
Author Profile
Kelly Walkovich
University of Michigan
Author Profile


Both vinblastine and low dose cytarabine therapy for Langerhans cell histiocytosis (LCH) have historically been delivered intravenously. Due to a vinblastine shortage and the SARS-CoV2 pandemic, frontline subcutaneous cytarabine was used to treat six pediatric patients with LCH with greater than 93% of the cytarabine doses administered at home by family. On average, 164 infusion chair hours (65.7 infusions) and 5,607 miles of driving were saved per patient, highlighting that subcutaneous cytarabine is a feasible treatment option for pediatric patients with LCH resulting in notably decreased patient travel burden and infusion center utilization.
17 Jul 2023Submitted to Pediatric Blood & Cancer
17 Jul 2023Assigned to Editor
17 Jul 2023Submission Checks Completed
17 Jul 2023Review(s) Completed, Editorial Evaluation Pending
17 Jul 2023Reviewer(s) Assigned
31 Jul 2023Editorial Decision: Revise Minor